Thiazolidinediones (TZDs) are a class of insulin-sensitizing drugs that improve glycemic control of type 2 diabetic patients mainly through targeting adipose tissue (Fig. 5).139 Mouse models of lipodystrophy demonstrate compromised responses to TZD treatment. Here, INS is linked to type 2 diabetes mellitus.